ArticleThe Journal of clinical investigation2019

Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.

David C Fajgenbaum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.